4-amino-2-nitrotoluene: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 8390 |
CHEMBL ID | 1350617 |
CHEBI ID | 81670 |
SCHEMBL ID | 100616 |
SCHEMBL ID | 17347354 |
MeSH ID | M0093596 |
Synonym |
---|
AC-1739 |
benzenamine, 4-methyl-3-nitro- |
4-methyl-3-nitroaniline |
2-nitro-4-aminotoluene |
3-nitro-p-toluidine |
m-nitro-p-toluidine |
3-nitro-4-methylaniline |
p-toluidine, 3-nitro- |
119-32-4 |
nsc7731 |
nsc-7731 |
4-amino-2-nitrotoluene |
5-nitro-4-toluidine |
3-nitro-4-toluidin |
wln: zr d1 cnw |
AC-907/25014173 |
4am2nt |
NCGC00091307-01 |
inchi=1/c7h8n2o2/c1-5-2-3-6(8)4-7(5)9(10)11/h2-4h,8h2,1h |
LS-614 , |
gl-amin [czech] |
nsc 7731 |
brn 0638984 |
einecs 204-314-0 |
ccris 3003 |
3-nitro-4-toluidin [czech] |
4-methyl-3-nitroaniline, 97% |
M-4200 |
STK387113 |
C18320 |
4-amino-1-methyl-2-nitrobenzene |
N0278 |
AKOS000119120 |
A804255 |
4-methyl-3-nitro-aniline |
NCGC00091307-02 |
4-methyl-3-nitro aniline |
(4-methyl-3-nitro-phenyl)-amine |
NCGC00257657-01 |
dtxcid805633 |
cas-119-32-4 |
dtxsid7025633 , |
tox21_200103 |
4-methyl-3-nitrobenzenamine |
sm8uz1q81f , |
gl-amin |
4-12-00-01997 (beilstein handbook reference) |
unii-sm8uz1q81f |
4-methyl-3-nitrophenylamine |
BP-20389 |
FT-0619031 |
PS-5957 |
AM20060491 |
AB00514384-03 |
SCHEMBL100616 |
CHEBI:81670 , |
SCHEMBL17347354 |
(4-methyl-3-nitrophenyl)amine |
4-methyl-3-nitro-phenylamine |
3-nitro-4-methyl-aniline |
CHEMBL1350617 |
1-amino-3-nitro-4-methylbenzene |
4-methyl-3-nitroaniline; |
mfcd00007910 |
F8880-0867 |
4-methyl-3-nitroaniline, analytical standard |
Q27155550 |
BCP32906 |
3-nitro-p-toluidine;3-nitro-4-methylaniline;4-amino-2-nitrotoluene |
NCGC00091307-03 |
3-nitro-4-methylanilin |
EN300-19073 |
Z104472590 |
Excerpt | Reference | Relevance |
---|---|---|
" A no-observed adverse effect level could not be determined." | ( Toxicity assessment of 4-amino-2-nitrotoluene. Houpt, JT; Johnson, MS; Leach, GJ; Reddy, G; Williams, LR, ) | 0.44 |
Class | Description |
---|---|
C-nitro compound | A nitro compound having the nitro group (-NO2) attached to a carbon atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 3.9811 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.0870 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
AR protein | Homo sapiens (human) | Potency | 30.8561 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 12.5893 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 56.4964 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 61.5660 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 10.9482 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 17.7828 | 0.0002 | 29.3054 | 16,493.5996 | AID588514 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 58.9909 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 31.6228 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 31.6228 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) |
plasma membrane | Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) |
plasma membrane | Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.62) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |